drugset / Trial / NCT07477808

Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer

NCT07477808

Phase 3 Not yet recruiting 116 enrolled Hunan Province Tumor Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a prospective, randomized, parallel-controlled clinical trial, primarily aimed at evaluating the level of body weight improvement of megestrol acetate combined with standard treatment compared with standard treatment in the first-line treatment of non-small cell lung cancer.

Timeline

Start
2026-04-01
Primary completion
2028-04-01
Completion
2029-04-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Megestrol Acetate Other / unclassified 625 mg Oral